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We have studied the population dynamics in response to selective drug pressure of mixtures of wild-type and mutant HIV
viruses exposed to either an inhibitor of the viral protease or a nonnucleoside allosteric inhibitor of the viral reverse
transcriptase. In order to quantitate mutant virus present in a mixed population, we developed a selective plaque assay,
which appears to be generally applicable to population dynamics studies where the viruses in question differ in the sensitivity
to a given drug by at least 10-fold. In this assay system, the titer of virus in a mixture is measured in the absence and
presence of a concentration of a specific inhibitor known to suppress virus replication by 99%. Virus detected in the presence
of inhibitor corresponds to mutant virus, whereas detection in the absence of drug results in quantitation of the total virion
population. Wild-type virus is then estimated by difference. Utilizing this system we studied the fate of mixtures of wild-type
and the protease-resistant mutant variant I84V in the presence and absence of the cyclic urea HIV protease inhibitor, DMP
450. We also examined the dynamics of mixtures of wild-type and the resistant mutant variant, L100I, in the presence and
absence of the drug DMP 266. In both systems we demonstrated that in the absence of drug, mutant virus is at a selective
disadvantage for growth compared to wild-type, whereas in the presence of a specific inhibitor, mutant virus exhibits the
selective growth advantage over wild-type virus. Better understanding of HIV population dynamics may allow the development
of superior inhibitors and the careful application of combination therapy in the clinical setting. q 1997 Academic Press
INTRODUCTION comparing the effects of particular mutations on intrinsic
GAG processing ability and resistance to inhibitors.
Critical to the usefulness of anti-HIV compounds is the Similarly, functional reverse transcriptase (RT) mutants
rapidity with which drug-resistant HIV variants appear in arise very quickly in vivo and in vitro, in response to both
HIV-infected individuals undergoing drug therapy. Many the competitive RT (nucleoside) and noncompetitive RT
potent inhibitors of HIV protease (Debouck and Metcalf, [nonnucleoside (NNRT)] inhibitors (DeClerq, 1993; Mel-
1990; Wlodawer and Erickson, 1993) and inhibitors of lors et al., 1995). These inhibitors also show differential
the reverse transcriptase (RT) (DeClerq, 1993) have been activity against HIV-1 WT (wild-type) and mutant strains
reported; viruses resistant to either of these inhibitor containing different amino acid substitutions in the RT
types have emerged both in vitro and in vivo (Winslow (Balzarini et al., 1993). Thus, critical to the development
and Otto, 1995; Mellors et al., 1995). of any inhibitor is the ability to model the population
The human immunodeficiency virus (HIV) protease is dynamics under drug selective pressure and to attempt
required for the processing of the GAG and GAG-POL to further the understanding of the mechanism of resis-
precursors which yield the structural proteins (capsid p24, tance. Doing so may allow the design of better inhibitors.
nucleocapsid p7 and p6, matrix p17) and enzymes (prote- In this report we describe the development and use
ase, reverse transcriptase, Rnase H, and integrase) of the of a sensitive plaque assay method to differentially quan-
mature infectious virion (Kohl et al., 1988; Darke et al., titate wild-type (WT) and drug-resistant HIVs in mixed
1988; Erickson-Viitanen et al., 1989). It is apparent, how- infections in the presence and absence of selective drug
ever, that protease mutants that result in drug resistance pressure for the purpose of studying viral population dy-
must retain sufficient enzyme activity to allow virus propa- namics. For the first study we chose the mutant virus
gation, while reducing susceptibility to the particular inhib- containing the Ile to Val change at position 84 in the
itor under study. The basis for this functional capability protease (I84V) and the corresponding WT RF. I84V HIV
is not entirely clear. Several models have recently been is 10-fold less sensitive to the cyclic urea inhibitor, DMP
suggested (Lin et al., 1995; Kuroda et al., 1995; Gulnik et 450 (Hodge et al., 1996). For the second study the virus
al., 1995; Tang and Hartsuck, 1995; Jacobsen et al., 1995; pair was composed of WT RF and the mutant virus con-
Tisdale et al., 1995; Condra et al., 1995; Markowitz et al., taining an leucine to isoleucine change at position 100
1995; Coffin, 1995; Mascher et al., 1996) for estimating in the HIV reverse transcriptase (L100I). L100I HIV is 30-
the relative fitness of various mutant protease HIVs by fold less sensitive to the inhibitor, DMP 266 (Young et
al., 1995; Winslow et al., 1996).
Because the WT and corresponding mutant virus (I84V1 To whom correspondence and reprint requests should be ad-
dressed. or L100I) exhibit at least a 10-fold difference in sensitivity
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to the drug selected (DMP 450 or DMP 266), we rea- to make stocks suitable for addition to the cell cultures
(DMSO £ 0.5%). This concentration of DMSO was foundsoned we would be able to detect WT and mutant vi-
ruses differentially in mixed infections by conducting to have no effect on the yield of infectious virus.
plaque assays in the absence and presence of inhibitor
(differential plaque assay). As shown below, in mixed Cells and virus strains
infections the total virus titer (WT plus either I84V or
The virus strains used in these studies were two pairsL100I) was selectively determined by performing the
of wild type (WT) and protease-resistant mutants (I84V) inplaque assay in the presence of a concentration of either
the RF (Hodge et al., 1996) and HXB2 backgrounds andDMP 450 or DMP 266 sufficient to inhibit WT virus by
one pair of RT-resistant mutants (L100I) in the RF back-99% (IC99), equivalent to 0.3 mM DMP 450 or 6 nM DMP
ground (Winslow et al., 1996). MT-2 cells (a CD4-positive266. [Measure plaque titer without inhibitor: Define T 
lymphoblastoid cell line) and HIV-1 RF were obtained fromtotal PFU/ml  WT / mutant (M). Measure plaque titer
D. Montefiore (Vanderbilt University, Nashville, TN). Thein the presence of inhibitor IC99 : Define M  PFU/ml
corresponding HIV-1 mutants, I84V and L100I HIV, weremutant. WT PFU/ml  T 0 M.
kindly provided by Sena Garber and Carol Reid of theAdditionally, in an attempt to further understand the influ-
DuPont Merck Pharmaceutical Co. L100I HIV was ob-ence of the I84V mutation on HIV protease activity and on
tained from tissue culture selection in peripheral bloodthe observed population shifts in mixed infections, we also
mononuclear cells (PBMCs) in response to DMP 266, ascompared Pr55gag polyprotein processing activity for the
previously described (Winslow et al., 1996). I84V HIV wastwo viruses, in the presence and absence of DMP 450.
also obtained by tissue culture selection in PBMCs inFor these experiments WT and I84V viruses derived from
response to selection with DMP 323 (Otto et al., 1994) H9HXB2 infectious molecular clones were used (Winslow et
cells and Molt 4 cells were obtained from the Americanal., 1994). Positions in the protease gene where these
Type Tissue Culture Collection (Rockville, MD). The vi-viruses differ are shown in Table 1. The RF or HXB2 back-
ruses derived from HXB2 infectious molecular clones wereground does not appear to affect the susceptibility to DMP
provided by L. Bacheler of the DuPont Merck Pharmaceuti-450 for either virus strain or the differences in susceptibility
cal Co. All viruses were passaged in H9 cells to preparebetween the WT and I84V in each pair.
viral stocks and titered in MT2 cells by standard plaqueOur results indicate that I84V HIV is at a significant
assay to permit accurate estimation of MOIs (Harada etselective disadvantage to WT in the absence of protease
al., 1985; Smallheer et al., 1993). The mixed infection stud-inhibitor, which correlates with poor processing ability,
ies were carried out in MT2 cells.whereas in the presence of drug, I84V has a significant
selective advantage. Similarly, L100I HIV is at a selective
Virus titersdisadvantage to WT in the absence of DMP 266, while in
the presence of drug, L100I HIV has a significant growth Titers (PFU/ml) were determined by plaque assay (Har-
advantage. ada et al., 1985; Smallheer et al., 1993). Briefly, suspensions
of progeny virus were serially diluted in RPMI-1640, and
MATERIALS AND METHODS 0.250 ml of each dilution was added to duplicate wells in a
12-well poly-L-lysine-coated culture plate (Sigma, preparedTest compounds
according to the method of Harada et al., 1993); each well
contained 2.25 ml of MT2 cells in RPMI-1640 at 51 105/DMP 266 and DMP 450 were dissolved in dimethyl
sulfoxide (DMSO) at 1 mg/ml and serially diluted in DMSO ml. These plates were incubated overnight at 367 in 3%
TABLE 1
Comparison of Amino Acid Differences and Virus Activities in the Presence and Absence of DMP 450 for WT
and I84V HIV in RF and HXB2 Backgrounds
DMP 450 IC90 (mM)
Amino acid position
Acute GAG
Virus strain infectiona processingb 10 13 37 41 84
HIV RF WT 0.15 0.24 I V N K I
HIV RF I84V 1.5 2.7 I V N K V
HIV HXB2 WT 0.12 0.13 L I S R I
HIV HXB2 I84V 1.2 1.8 L I S R V
a The concentration of DMP 450 showing 90% reduction yield of infectious particles as measured by plaque assay.
b The IC90 for inhibition of Pr55gag processing was measured by radioimmuneprecipitation and band quantitation by AMBIS Radioanalytic Scanner
(22).
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FIG. 1. (A) WT and I84V growth kinetics in the absence (circles and squares, respectively) or presence (diamonds or triangles) of 0.3 mM DMP
450. The plaque assay was performed in the presence (closed symbols) or absence (open symbols) of 0.3 mM DMP 450. (B) WT and L100I growth
kinetics in the absence (circles and squares, respectively) or presence (diamonds or triangles) of 60 nM DMP 266. The plaque assay was performed
in the presence (closed symbols) or absence (open symbols) of 6 nM DMP 266.
CO2 to allow efficient attachment of cells to the plate and simultaneous titer of the same virus containing sample in
the presence of an inhibitor with at least a 10-fold differ-virus infection of the cells. Liquid containing free virus and
unattached cells were removed prior to addition of 1.0 ml ence in sensitivity for the WT and mutant virus pair chosen
for study. DMP 450 (0.3 mM) was added to the WT andof RPMI-1640 with 0.75% (wt/vol) SeaPlaque agarose (FMC
Corp.) and 5% fetal bovine serum (FBS). Plates were incu- the protease mutant I84V HIV duplicate titers; whereas 6
nM DMP 266 was added to the WT and L100I duplicatebated for 3 days and a second 0.5 ml RPMI-agarose over-
lay was added. After an additional 3 days a final overlay titers. These concentrations were observed to inhibit WT
virus 99% (IC99) as determined by the plaque titer assay.of 1 ml phosphate-buffered saline (PBS, Sigma) with 0.75%
agarose and 1 mg of the tetrazolium dye MTT [3-(4,5-di- The inhibitor was added to the initial infection, the first 1
ml agarose/RPMI overlay and the second 0.5 ml agarose/methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma]
per milliliter was added. The plates were again incubated RPMI overlay; compound was not added to the final aga-
rose/MTT staining. The data points presented for the virusovernight. Clear plaques in a purple background were
titers determined for each mixed infection study are thecounted, and the number of PFU/ml of virus was calculated
average from at least two differential plaque assays.for each sample.
HIV p24 ELISA assay of culture fluidsDifferential plaque assay
The amount of HIV-1 p24 released in to the cell-freeThe differential plaque assay is identical to the plaque
titer assay described above, but includes the additional supernatant was determined using the DuPont HIV-1 p24
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Core Profile ELISA kit (DuPont NEN Research Products,
NEK-060). The manufacturers directions were followed
for sample preparation.
Mixed infection studies
Infections were performed simultaneously in the ab-
sence and presence of either 0.3 mM DMP 450 (WT:I84V
study) or 60 nM DMP 266 (WT:L100I study). The total
m.o.i. for the WT:I84V DMP 450 study was 0.005 PFU/
cell and the ratio of WT:I84V was 95%:5%. The total m.o.i.
for the WT:L100I DMP 266 study was 0.03 PFU/cell. Three
different ratios of WT:L100I were examined: 11%:89%,
59%:41%, and 98%:2%. Duplicate flasks, each containing
80 ml at 5 1 105 MT2 cells per milliliter, were infected
with either WT HIV-1 RF, mutant HIV (I84V or L100I), or FIG. 2. Correspondence between calculated input PFU of I84V virus
a mixture of WT and I84V or L100I viruses. Inhibitor was and measured plaques in mixtures of I84V and WT virus plaque as-
sayed in the presence of DMP 450. Mixtures of I84V and WT HIV atadded to one complete set of flasks, while the duplicate
ratios ranging from 0.1 to 50% I84V were prepared in culture media.flasks remained without inhibitor. After 3 hr any unad-
These mixtures, containing 200 to 2000 total PFU/ml, were calculated tosorbed virus was removed by centrifugation at 1000 g
contain 1 to 1000 PFU/ml of I84V. Plaque assays were then performed in
for 5 min, followed by a 50-ml wash with RPMI-1640 both the absence and presence of a 0.3 mM DMP 450 on aliquots of
media, resuspension in 80 ml of the same media with or these mixtures. The results are plotted to show the measured number
without appropriate inhibitor (0.3 mM DMP 450 or 60 nM of plaques as a function of the calculated number of input I84V in the
various mixtures.DMP 266) in a T-250 tissue-culture flask and incubation
at 377, 3% CO2 . Ten milliliters of cells and culture fluids
were harvested on Days 1–4 and 7. Cells and culture
noprecipitation with an antibody to HIV-1 p24 (Keneallyfluids were separated by low-speed centrifugation; pel-
et al., 1987). Molt4 cells chronically infected with eitherlets were saved and culture fluids aliquoted in 1-ml por-
HXB2 WT or I84V HIV were prepared, treated with inhibi-tions; all samples were frozen at 0807. All culture fluid
tor DMP 450, and radioimmunoprecipitated, as describedsamples were titered by differential plaque assay at the
previously (Rayner et al., 1994). Briefly, 106 chronicallyconclusion of experiment. The input virus was titered by
infected cells were treated with fivefold serial dilutionsdifferential plaque assay on Day 0.
of compound in RPMI-1640 tissue culture medium and
Radioimmunoprecipitation (RIPS) of intracellular viral incubated at 377 overnight. The cells were collected by
proteins centrifugation, resuspended in 0.5 ml Dulbecco’s minimal
HIV-1 Pr55gag polyprotein processing, both in the ab- essential medium (DMEM) lacking cysteine and methio-
sence or presence of DMP 450, was assessed by immu- nine, and incubated for 1 hr at 377. [35S]Cysteine and
[35S]methionine (50 mCi each, DuPont NEN) were then
TABLE 2 added for an additional 4 hr incubation at 377. The cells
and culture fluids were separated by centrifugation. ViralDifferential Plaque Assay
polyprotein processing was assessed by radioimmuno-
PFU/ml PFU/ml 0.3 mM Percentage recovered precipitation (RIP) of cell-associated viral proteins and
0 DMP 450 DMP 450 0.3 mM DMP 450 cell-free virus (Ikuta and Luftig, 1986) by use of an anti-
body (Kenealy et al., 1986) to viral p24 and sodium dode-
A. Wild-type virus
cycl sulfate–polyacrylamide gel electrophoresis followed
200 0 0 by fluorography. Bands corresponding in molecular
260 0 0 weight to Pr55gag and Pr24gag were quantitated by an
896 0 0
Ambis Radioanalytic Scanner (San Diego, CA).2000 2 0.1%
220000 200 0.1%
260000 2000 0.77% RESULTS
580000 2400 0.4%
Ability of differential plaque assay to discriminateB. I84V virus
100 98 98% between WT and corresponding mutant viruses
334 345 101%
770 784 102% Preliminary experiments to test the feasibility of this
960 962 100% approach explored the ability of the differential plaque
1000 1060 106% assay to discriminate between WT and I84V HIV or WT
514000 534000 104%
and L100I. In the presence of a protease inhibitor during
the differential-plaque titer (0.3 mM DMP 450), the numberNote. Detection of wild-type (WT) and I84V mutant virus plaqued in
the presence and absence of an 0.3 mM DMP 450. of plaques of WT virus detected was approximately 0.5%
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FIG. 3. Population dynamics of mixtures of WT and I84V in response to selective drug pressure. Graph [A] PFU/ml; Graph [B] Percentage total
virus. Open symbols are mixed infections grown in the absence of DMP 450, while closed symbols are mixed infections grown in the presence of
0.3 mM DMP 450. WT virus is represented by square symbols (h, j), while I84V is represented by open or closed triangles (n, m). The corresponding
horizontal lines represent the input WT and I84V virus titers for both the untreated and treated mixtures on Day 0.
the number observed in the absence of drug, over a 2000- 99%:1%. This WT:I84V ratio was chosen to model what
may be likely in the clinic, when low levels of a mutantfold range of viral titers (Table 2A). In contrast, the I84V
mutant virus produced the same number of plaques in virus preexist within a larger WT population, and therapy
is initiated. At this m.o.i. MT2 cells lyse in approximatelythe presence or absence of this concentration of DMP
450 (Table 2B). As shown in Fig. 1A the growth kinetics 3–4 days, but a sequential reinfection system allowed
of I84V mutant virus were unaffected by the presence of the infections to be extended indefinitely. Results from
0.3 mM DMP 450, during the growth phase or the plaque these experiments (data not shown) revealed that in the
phase, while the WT growth kinetics are reduced 95– presence of protease inhibitor I84V had become 73% of
100% under the same circumstances. The growth kinetics the total mixture at the end of the first 4-day infection
of both the untreated and 60 nM DMP 266-treated L100I and 100% by the end of the second infection (cumulative
mutant virus was unaffected by 6 nM DMP 266 during
the plaque phase (data not shown). However, WT HIV
PFUs were completely suppressed when DMP 266 was
present in either the growth phase or plaque phase (com-
pare open and closed symbols symbols in Fig. 1B).
Correspondence between calculated and measured
PFU
Next we examined whether there was a correspon-
dence between calculated input PFU of I84V virus and
the measured plaques in mixtures of I84V and WT virus
determined in the presence of DMP 450. Mixtures of I84V
and WT HIV at ratios ranging from 0.1 to 50% I84V were
prepared in culture media. Plaque assays were then per-
formed in both the absence and presence of 0.3 mM
DMP 450 on aliquots of these mixtures. The mixtures,
containing 200 to 2000 total PFU/ml, were calculated to
contain amounts of I84V ranging from 1 to 1000 PFU/ml.
The results, shown in Fig. 2, indicated good correspon- FIG. 4. Growth kinetics as measured by p24 Elisa for the same
culture fluids from Fig. 1 (viruses grown alone) and Figs. 3A and 3Cdence for calculated and measured PFU/ml for I84V, es-
(for mixed infections). Open square, WT virus grown in the absence ofpecially at levels above 1% (r2 value 0.919 for all points).
DMP 450; closed square, WT virus grown in the presence of 0.3 mM
DMP 450; open triangle, I84V virus grown in the absence of DMP 450;Mixed infection studies
closed triangle, I84V virus grown in the presence of 0.3 mM DMP 450;
For the initial virus mixing experiment, the total m.o.i. open circle 95%:5% WT:I84V grown in the absence of DMP 450; closed
circle, 95%:5% WT:I84V grown in the presence of 0.3 mM DMP 450.was 0.02 PFU/cell and WT and I84V were mixed at
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FIG. 5. Population dynamics of mixtures of WT and L100I from three different initial ratios of WT:L100I in response to selective drug pressure.
Graphs A and D represent the population dynamics for WT:L100I initial mixture 97%:3%; graphs B and E represent WT:L100I, 61%:39%; graphs C
and F, 12%:88%. Graphs A–C, PFU/ml; graphs D–F, percentage total virus. Open symbols are mixed infections grown in the absence inhibitor,
while closed symbols are mixed infections grown in the presence of 60 nM DMP 266. WT virus is represented by square symbols (h, j), while
L100I is represented by triangles (n, m). The corresponding dashed horizontal lines represent the input WT and L100I virus titers in both untreated
and treated mixtures on Day 0.
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Day 8), although the total PFUs were only slightly greater titer increased 14-fold. The relative proportions of WT
and mutant virus was 95%:5% on Day 7, essentially identi-than the I84V PFU input, suggesting a slow absolute
growth rate for the mutant virus. cal to the input ratio, suggesting that L100I virus com-
petes effectively in the presence of large numbers of WTBecause the population dynamics appeared to be
rapid, a second series of experiments was designed to virus. However, when this same mixture was grown in
the presence of 60 nM DMP 266, at Day 7 the total titerfollow the kinetics daily for 7 days. A lower total m.o.i.
(0.005 PFU/cell) was used to permit the infections to increased 23-fold with the individual WT titer increasing
3-fold and the L100I titer increased 786-fold. The relativecontinue for 7 days without addition of more cells. A
95%:5% (WT:I84V) mixture grown for 7 days in the ab- ratio shifted to 88% mutant by Day 7.
When the proportions of WT and L100I were closer atsence of drug increased in total titer 20-fold (Fig. 3A,
open symbols) and changed in ratio to 99.75% WT:0.25% initial infection (61%:39%), as shown in Figs. 5B and 5E,
the total titer increased 7-fold in the absence of DMPI84V (Fig. 3B, open symbols). In contrast, the same mix-
ture grown in 0.3 mM DMP 450 for 7 days remained 266; this total was composed of an 8-fold increase in WT
and a 5-fold increase in L100I. In this experiment, DMPessentially constant in total titer (Fig. 3A, closed sym-
bols), but changed in ratio of WT:I84V to 70:30 at 3 days 266 appeared to have a small relative disadvantage for
growth in the absence of drug; the proportion of mutantand 2:98 at 7 days (Fig. 3B, closed symbols). The p24
values (Fig. 4), which cannot distinguish between WT or fell from 39% at input to 30% at Day 7. The corresponding
DMP 266-treated infection total titer increased 55-foldI84V virus, were determined on these samples. The re-
sults confirmed the infectivity titers, especially the low from the initial infection; in the presence of DMP 266;
L100I dominated the mixture from Day 1 and becametotal virus titers observed for the DMP 450 treated WT
(Fig. 1, open and closed diamonds) and the WT plus I84V 63% of the mixture by Day 7.
When the initial ratio for WT:L100I was 12%:88%, andinfection (Fig. 3A, closed symbols).
A third series of infection studies with the virus pair, in the absence of DMP 266, the proportions of the two
viruses changed to 20%:80% at Day 7 (Figs. 5C andWT RF and the corresponding DMP 266 mutant, L100I
HIV, examined the population dynamics in the absence 5F), again suggestive of L100I having a subtle kinetic
disadvantage for growth compared to WT virus. Theand presence of 60 nM DMP 266 (approximately 100-
fold the IC90 for the WT virus and approximately the IC60 WT:L100I ratio after 7-days from the corresponding
DMP-266 treated mixed infection changed to 8%:92%.for mutant L100I virus). To examine population dynamics
from different initial population ratios of WT and L100I, Again an increase in the total titer compared to the
untreated infection was observed (23-fold compared tothree different initial mixed infections of WT and L100I
were studied. Initial mixtures where either WT or L100I 8-fold); this increase was composed of a 3-fold increase
in WT and a 786-fold increase in L100I. The results withwere clear majority populations, and a condition where
WT and mutant were nearly equal were examined DMP 266 treatment of WT/L100I mixtures are similar to
what we observed for the HIV protease mutant mixture(WT:L100I ratios  97%:3%, 61%:39%, and 88%:12%, re-
spectively). experiments in illustrating the selective advantage re-
sistant mutants have over corresponding wild-type virusThe virus titers over 7-days for WT and L100I HIV in
the mixed infections are shown in Figs. 5A–5F; Table 3 when drug pressure is applied. However, the relative
growth disadvantage the mutant viruses appear to ex-summarizes the initial titers and 7-day titers and the fold-
change for each mixture. When the WT:L100I ratio was hibit in the absence of drug pressure are different in
magnitude. I84V virus is quickly selected against when97%:3% initially (Figs. 5A and 5D), and in the absence of
DMP 266, the total titer increased 8-fold by Day 7, with DMP 450 is absent, whereas L100I titers are more sub-
tly altered.the individual WT titer increasing 8-fold, and the L100I
TABLE 3
WT and L100I HIV Titers from Untreated and 60 nM DMP266-Treated Infections
Initial Day 7
Titer Growth Titer total Fold-
WT%:L100I% (PFU/ml) /DMP 266 (PFU/ml) change WT%:L100I%
97:3% 2.8 1 104 0 2.31 1 105 8 95%:5%
97:3% 2.8 1 104 / 6.72 1 105 23 12%:88%
61%:39% 1.81 1 104 0 2 1 105 7 70%:30%
61%:39% 1.81 1 104 / 1.58 1 106 55 37%:63%
12%:88% 1.68 1 104 0 4.08 1 105 23 20%:80%
12%:88% 1.68 1 103 / 1.2 1 106 81 8%:92%
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FIG. 6. Radioimmunoprecipitation (RIPS) (A, C) and corresponding quantitation (B, D) using cells chronically infected with HXB2 WT (A, B) and
HXB2 I84V (C, D) virus. The positions of viral GAG p55 and p24 are indicated. Concentrations of DMP 450 were a, 1.6 mM; b, 0.3 mM; c, 0.07 mM;
d, 0.013 mM; e, untreated control.
Effects of DMP 450 on Pr55gag polyprotein ent IC90 similar to that observed in acute infections
(Table 1).processing in WT and I84V HIV
To examine the effects of the I84V mutation in HIV
DISCUSSION
protease on enzyme activity within the virus, Pr55gag
polyprotein processing was assessed by radioimmuno- Our results indicate that I84V is at a significant selec-
tive disadvantage to WT in the absence of protease inhib-precipitation (RIP) with an antibody to HIV p24. These
RIP studies (Figs. 6A – 6D) revealed that even in the itor, which correlates with poor processing ability;
whereas in the presence of drug, I84V has a significantabsence of DMP 450, I84V virus contained a 3-fold in-
crease in unprocessed Pr55gag polyprotein precursor selective advantage. Kuroda et al. (1995) have also ob-
served a delay in appearance of mature p24 for the I84Vcompared to the WT virus. However, the apparent pat-
tern of cleavage based on molecular mass of p24-reac- mutant virus by probing infected cells with HIV-positive
human sera. This data is also consistent with the in-tive components was essentially the same as for WT.
In the presence of DMP 450, however, the amount of creased Km values and decreased efficiencies observed
with the I84V protease compared to the WT protease, atprocessed p24 was decreased for I84V HIV and the ratio
of p55 precursor to mature p24 product correspondingly least with fluorogenic peptide substrates (R. Klabe, Du-
Pont Merck, unpublished data; Croteau et al., 1997).increased in a dose-dependent manner, with an appar-
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man immunodeficiency virus type I reverse transcriptase resistanceThus, one consequence of the I84V mutation is to de-
to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37,crease the enzyme’s ability to catalyze maturation of the
1576–1579.
viral core precursor to the final products required for Coffin, J. M. (1995). HIV population dynamics in vivo: Implications for
virus assembly. This delayed (slower) processing is likely genetic variation, pathogenesis, and therapy. Science 267, 483–489.
Condra, J. H., Schleif, W. S., Blahy, O. M., Gabryelski, L. J., Graham, D. J.,a major reason that, in the absence of drug, the I84V
Quintero, J. C., Rhodes, A., Robbins, H. L., Rothe, E., Shivaprokash,virus is at a significant selective disadvantage relative to
M., Titus, D., Yang, T., Toppler, H., Squires, K. E., Deutsch, P. J., andWT, as shown in the present study and by El-Farrash et
Emini, E. A. (1995). In vivo emergence of HIV-1 variants resistant to
al. (1994). The deleterious nature of this particular muta- multiple protease inhibitors. Nature 374, 569–571.
tion may explain the inability to detect it genotypically in Croteau, G., Doyon, L., Thibeault, D., McKercher, G., Pilote, L., and
Lamarre, D. (1997). Impaired fitness of human immunodeficiencyuntreated individuals to date (Lech et al., 1996).
virus type I variants with high-level resistance to protease inhibitors.The population dynamics of the WT and L100I mixed
J. Virol. 71, 1089–1096.infections also show that L100I is at a selective disadvan-
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